# Aspen Neuroscience

Canonical page: https://technooptimist.io/companies/aspen-neuroscience
San Diego company that turns each Parkinson's patient's own skin cells into dopamine-neuron precursors and implants them in the brain, so no immune suppression is needed.

## In brief

- Sasineprocel (ANPD001): 15 patients dosed in the ASPIRO phase 1/2a by June 2026.
- 12-month data: about 2 more hours a day of good symptom control, without immunosuppression.
- San Diego GMP plant built for pivotal-trial manufacturing; preparing a phase 3 package.

## Facts

- Headquarters: US
- Status: private
- Website: https://aspenneuroscience.com
- Frontiers: [Biotech](https://technooptimist.io/biotech.md) (Replacement cells)

## Programs

- [Sasineprocel (ANPD001)](https://technooptimist.io/biotech/sasineprocel.md) (Biotech): Proto; next: Phase 3 alignment with regulators (2026). Phase 1/2a fully dosed (15 patients); 12-month gains reported; preparing for phase 3.

## Latest updates

- **9 Jul 2026**: Aspen completes ASPIRO dosing with a frozen, ready-to-inject cell product ahead of phase 3. Aspen finished dosing cohorts 3 and 4 of its phase 1/2a trial, bringing the total to 15 patients. ([our story](https://technooptimist.io/stories/aspen-completes-aspiro-dosing-with-a-frozen-ready-to-inject-cell-cc8e4ff2.md) · [original source](https://www.pharmanow.live/latest-news/aspen-neuroscience-aspiro-cohort-3-4-dosing-sasineprocel-phase-3))
- **18 Mar 2026**: Aspen reports 12-month ASPIRO data: patient-derived dopamine cells improve Parkinson's symptoms without immunosuppression. In a late-breaking talk at AD/PD 2026, Aspen showed one-year results for the first eight patients given dopamine-neuron precursors grown from their own skin cells. ([our story](https://technooptimist.io/stories/aspen-reports-12-month-aspiro-data-patient-derived-dopamine-cells-2a7330f8.md) · [original source](https://aspenneuroscience.com/aspen-neuroscience-announces-positive-12-month-data-from-its-aspiro-clinical-trial-in-a-late-breaking-oral-presentation-at-t/))

## Partners, customers and investors

- California Institute for Regenerative Medicine (investor): Funds the ASPIRO trial (grant CLIN2-15547).

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.